scholarly journals Chronic granulocytic leukemia: cytogenetic conversion of the bone marrow with cycle-specific chemotherapy

Blood ◽  
1977 ◽  
Vol 50 (1) ◽  
pp. 107-113 ◽  
Author(s):  
RV Smalley ◽  
J Vogel ◽  
CM Jr Huguley ◽  
D Miller
Keyword(s):  
Bone Marrow ◽  
Complete Remission ◽  
Drug Treatment ◽  
Cytosine Arabinoside ◽  
Fatal Outcome ◽  
The Other ◽  
Nausea And Vomiting ◽  
Chronic Granulocytic Leukemia ◽  
Negative State ◽  
Granulocytic Leukemia

Abstract Sixteen patients with Ph1-positive chronic granulocytic leukemic (CGL) were entered on a pulsing chemotherapy program consisting of cytosine arabinoside 100 mg/sq m/day X 5 and thioguanine 100 mq/sq m/day X 5 every 21 days in an attempt to convert the Ph1-positive marrow to a Ph1- negative state and thereby achieve a complete remission. Twelve patients had an adequate trail of drug treatment, and ten of these had adequate chromosome examinations. There were two “conversions,” one of which was maintained for 5+ mo, while the other was transient. The program was unacceptable, however, to most patients due to intolerable nausea and vomiting. Thus a prospective chemotherapeutic attempt to convert a Ph1-positive marrow without splenectomy has induced a conversion in two of ten patients. Other regimens which might induce less nausea and vomiting and a higher rate of conversions should be sought in future attempts to alter the invariably fatal outcome of CGL.

scholarly journals Chronic granulocytic leukemia: cytogenetic conversion of the bone marrow with cycle-specific chemotherapy

Blood ◽  
1977 ◽  
Vol 50 (1) ◽  
pp. 107-113 ◽  
Author(s):  
RV Smalley ◽  
J Vogel ◽  
CM Jr Huguley ◽  
D Miller
Keyword(s):  
Bone Marrow ◽  
Complete Remission ◽  
Drug Treatment ◽  
Cytosine Arabinoside ◽  
Fatal Outcome ◽  
The Other ◽  
Nausea And Vomiting ◽  
Chronic Granulocytic Leukemia ◽  
Negative State ◽  
Granulocytic Leukemia

Sixteen patients with Ph1-positive chronic granulocytic leukemic (CGL) were entered on a pulsing chemotherapy program consisting of cytosine arabinoside 100 mg/sq m/day X 5 and thioguanine 100 mq/sq m/day X 5 every 21 days in an attempt to convert the Ph1-positive marrow to a Ph1- negative state and thereby achieve a complete remission. Twelve patients had an adequate trail of drug treatment, and ten of these had adequate chromosome examinations. There were two “conversions,” one of which was maintained for 5+ mo, while the other was transient. The program was unacceptable, however, to most patients due to intolerable nausea and vomiting. Thus a prospective chemotherapeutic attempt to convert a Ph1-positive marrow without splenectomy has induced a conversion in two of ten patients. Other regimens which might induce less nausea and vomiting and a higher rate of conversions should be sought in future attempts to alter the invariably fatal outcome of CGL.

scholarly journals Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy

Blood ◽  
1976 ◽  
Vol 47 (6) ◽  
pp. 1003-1009 ◽  
Author(s):  
GP Canellos ◽  
VT DeVita ◽  
J Whang-Peng ◽  
BA Chabner ◽  
PS Schein ◽  
...  
Keyword(s):  
Complete Remission ◽  
Cytosine Arabinoside ◽  
Philadelphia Chromosome ◽  
Chronic Phase ◽  
Blast Cell ◽  
Response To Therapy ◽  
Chronic Granulocytic Leukemia ◽  
Blastic Phase ◽  
Response To Chemotherapy ◽  
Granulocytic Leukemia

Abstract Thirty-two patients in the blastic phase of Philadelphia chromosome- positive chronic granulocytic leukemia (CGL) were studied in a prospective randomized trial in which vincristine--prednisone (19 patients) was compared with cytosine arabinoside--6-thioguanine (13 patients). Seven remissions (37%), including two complete remissions, were achieved in the vincristine--prednisone group. Three of the five with predominant hypodiploid blast cell lines treated with vincristine-- prednisone had complete or partial remissions. Both complete remitters presented with hypodiploidy consisting of 44 chromosomes. Four patients (30%) who were treated with cytosine arabinoside--6-thioguanine responded with one complete remission. The median survival of the responders was 8 mo, as compared to 1--2 mo for the nonresponders. Crossover to the opposite regimen as secondary therapy following refractoriness or resistance resulted in only 3 partial responses out of 21 treated. All three had previously responded to vincristine-- prednisone. Of the 32 cases, 14 had an elective splenectomy during the chronic phase of the disease. Prior splenectomy did not influence the response to chemotherapy, as all three complete remitters occurred in the nonsplenectomized group. Similarly, survival in the blastic phase was not affected by prior splenectomy.

scholarly journals Chronic Granulocytic Leukemia and the Philadelphia Chromosome

Blood ◽  
1963 ◽  
Vol 21 (2) ◽  
pp. 183-196 ◽  
Author(s):  
P. H. FITZGERALD ◽  
ANGELA ADAMS ◽  
FREDERICK W. GUNZ
Keyword(s):  
Complete Remission ◽  
Acute Phase ◽  
Chromosome Abnormality ◽  
Philadelphia Chromosome ◽  
The Other ◽  
Direct Examination ◽  
Chronic Granulocytic Leukemia ◽  
The One ◽  
Granulocytic Leukemia ◽  
Very High

Abstract Twelve patients with chronic granulocytic leukemia were examined for the presence of the Ph1 chromosome abnormality at various stages of their disease. The abnormality was demonstrated either in the blood or marrow of all patients. Patients in relapse showed very high numbers of Ph1-positive mitoses in both blood and marrow; those in remission showed relatively few or no positives in the blood but sizeable numbers in the marrow. There was a positive correlation between the degrees of abnormality of blood and marrow on the one hand, and the percentage of Ph1-positive mitoses on the other. Direct examination of the marrow for the demonstration of the Ph1 appeared of particular value in the acute phase of chronic granulocytic leukemia. It seemed likely that therapy depressed the number of abnormal (Ph1-positive) mitoses. There was, however, no evidence that these ever disappeared from the marrow, even in complete remission. The findings presented and those in the literature did not make it possible to decide in what way the Ph1 chromosome abnormality is related to the onset of leukemia.

scholarly journals Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy

Blood ◽  
1976 ◽  
Vol 47 (6) ◽  
pp. 1003-1009
Author(s):  
GP Canellos ◽  
VT DeVita ◽  
J Whang-Peng ◽  
BA Chabner ◽  
PS Schein ◽  
...  
Keyword(s):  
Complete Remission ◽  
Cytosine Arabinoside ◽  
Philadelphia Chromosome ◽  
Chronic Phase ◽  
Blast Cell ◽  
Response To Therapy ◽  
Chronic Granulocytic Leukemia ◽  
Blastic Phase ◽  
Response To Chemotherapy ◽  
Granulocytic Leukemia

Thirty-two patients in the blastic phase of Philadelphia chromosome- positive chronic granulocytic leukemia (CGL) were studied in a prospective randomized trial in which vincristine--prednisone (19 patients) was compared with cytosine arabinoside--6-thioguanine (13 patients). Seven remissions (37%), including two complete remissions, were achieved in the vincristine--prednisone group. Three of the five with predominant hypodiploid blast cell lines treated with vincristine-- prednisone had complete or partial remissions. Both complete remitters presented with hypodiploidy consisting of 44 chromosomes. Four patients (30%) who were treated with cytosine arabinoside--6-thioguanine responded with one complete remission. The median survival of the responders was 8 mo, as compared to 1--2 mo for the nonresponders. Crossover to the opposite regimen as secondary therapy following refractoriness or resistance resulted in only 3 partial responses out of 21 treated. All three had previously responded to vincristine-- prednisone. Of the 32 cases, 14 had an elective splenectomy during the chronic phase of the disease. Prior splenectomy did not influence the response to chemotherapy, as all three complete remitters occurred in the nonsplenectomized group. Similarly, survival in the blastic phase was not affected by prior splenectomy.

Successful Treatment of Juvenile Chronic Granulocytic Leukemia With Marrow Transplantation

PEDIATRICS ◽  
1979 ◽  
Vol 63 (1) ◽  
pp. 44-46
Author(s):  
Jean E. Sanders ◽  
C. Dean Buckner ◽  
Patricia Stewart ◽  
E. Donnall Thomas
Keyword(s):  
Bone Marrow ◽  
Maintenance Therapy ◽  
Total Body Irradiation ◽  
Marrow Transplantation ◽  
Marrow Transplant ◽  
Successful Outcome ◽  
Chronic Granulocytic Leukemia ◽  
Total Body ◽  
Granulocytic Leukemia ◽  
Disease Free

A 46-month-old boy with juvenile chronic granulocytic leukemia was treated intensively with hydroxyurea dimethyl myleran, cyclophosphamide, and total body irradiation. He then received a marrow transplant from an HL-A matched brother. Thirty-two months after the transplantation, he is hematologically normal and remains disease free on no-maintenance therapy. The successful outcome of this case suggests that a bone marrow transplant for any patient with a suitable histocompatible donor should be considered in the treatment of this disease.

Bone marrow transplantation for chronic granulocytic leukemia

Cancer ◽  
1986 ◽  
Vol 58 (10) ◽  
pp. 2307-2311 ◽  
Author(s):  
Andrea Bacigalupo ◽  
Francesco Frassoni ◽  
Maria Teresa van Lint ◽  
Domenico Occhini ◽  
Pier Antonio Pittaluga ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Chronic Granulocytic Leukemia ◽  
Granulocytic Leukemia

scholarly journals Karyotypic polymorphism in acute myelofibrosis

Blood ◽  
1982 ◽  
Vol 60 (4) ◽  
pp. 841-844 ◽  
Author(s):  
I Shah ◽  
K Mayeda ◽  
F Koppitch ◽  
S Mahmood ◽  
B Nemitz
Keyword(s):  
Bone Marrow ◽  
Peripheral Blood ◽  
Black Male ◽  
Blood Cells ◽  
Normal Karyotype ◽  
Trisomy 8 ◽  
Chronic Granulocytic Leukemia ◽  
Cytogenetic Abnormalities ◽  
Granulocytic Leukemia

Abstract Acute myelofibrosis (AMF) was diagnosed in a 59-yr-old black male in September 1978, on the basis of pancytopenia, lack of hepatosplenomegaly, fibrosis of the marrow, and paucity of teardrop red blood cells in the peripheral blood. Since then the patient has demonstrated an unusually long survival of 36 mo with a changing cytogenetic course. His initial 46, XY normal karyotype changed in 20 mo to trisomy 8, followed 1 yr later by 1:4 translocation in peripheral blood. Simultaneously with these changes, the fibrosis in the bone marrow progressively decreased, ultimately terminating in chronic granulocytic leukemia-like presentation with reversal to 46, XY karyotype. Fibroblast culture failed to show any evidence of cytogenetic abnormalities. The disappearance of fibrosis confirmed by trichrome and reticulin stains and lack of cytogenetic abnormalities in fibroblasts confirms the secondary role of fibrosis.

Sign in / Sign up

Export Citation Format

Share Document